Skip to content

Incidence and Risk Factors of Low Anterior Resection Syndrome

Incidence, Risk Factors Of Low Anterior Resection Syndrome And Validation Of LARS Score Among Egyptian Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06359730
Enrollment
120
Registered
2024-04-11
Start date
2017-12-01
Completion date
2022-12-01
Last updated
2024-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Keywords

rectal cancer, anterior resection, LARS

Brief summary

Sphincter sparing surgery is oftentimes associated with bowel dysfunction complaints, namely the low anterior resection syndrome (LARS). The LARS questionnaire is widely used to assess this syndrome. With advances in colorectal surgery, sparing sphincter surgeries are gaining popularity. But symptoms after surgery can affect the quality of life which has psychomotor effects. Low anterior resection syndrome score is a worldwide known questionnaire. Many countries have accredited validation and translation of this questionnaire, but to our knowledge; it is the first time in Egypt.

Interventions

OTHERLARS score questionnaire

LARS score questionnaire is filled by the patient after anterior resection for rectal cancer to study the quality of life

Sponsors

Zagazig University
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Age more than 18 * Diagnosed patients with rectal adenocarcinoma and who received low anterior resection with anastomosis creation or after a minimum 6 months interval after stoma reversal. * Tumors of the rectum (2-15 cm) from anal verge

Exclusion criteria

* • cognitive dysfunction * Having a history of inflammatory bowel disease or any disease with bowel function impairment namely, Crohn's disease, irritable bowel syndrome, ulcerative colitis or others. * Age less than 18 * Metastatic cancer or tumor recurrence * Rectal tumors within 2 cm from anal verge( abdominoperineal)

Design outcomes

Primary

MeasureTime frameDescription
agefrom 2017 to 2022age of the patients in years was recorded from patient records
sexfrom 2017 to 2022sex of patients was recorded from patient records
medical diseasefrom 2017 to 2022medical disease like diabetes and hypertension was recorded from patient records
site of tumorfrom 2017 to 2022tumor site was determined in Cm from anal verge by colonoscopy
neoadjuvant therapyfrom 2017 to 2022history of neoadjuvant therapy before surgery was obtained from patients records
site of anastmosisfrom 2017 to 2022site of anastmosis after resection was recorded as colo-rectal or colo-anal
type of meso-rectal excisionfrom 2017 to 2022excision of meso-rectum was recorded if it was partial or complete
adjuvant therapyfrom 2017 to 2022it was recorded from patients records if he\\she had chemo- or radiotherapy post-operatively
type of surgeryfrom 2017 to 2022from records; surgery was open or laparoscopic
type of anastmosisfrom 2017 to 2022type of anastmosis(hand sewen or stappled) obtained from records
LARS scorefrom 2017 to 2022obtained by LARS questionnaire filled by the patient during follow up, it was formed of five questions with different scores on answer choices, interpretaion (0-20) means no LARS, (21- 29) means minor LARS, (30-42) means major LARS

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026